Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Namrata Vijayvergia"'
Autor:
Jasmeet Kaur, Namrata Vijayvergia
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8653-8664 (2023)
Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs) are a diverse group of rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas, and they can vary significantly in terms of clinical behavior and prognosi
Externí odkaz:
https://doaj.org/article/8378af0037664236bc473da5cc4968f9
Publikováno v:
Cancers, Vol 14, Iss 11, p 2695 (2022)
Background: Dual utilization of the immune checkpoint inhibitors (ICPIs) nivolumab plus ipilimumab has demonstrated clinical promise in the treatment of patients with refractory high-grade neuroendocrine neo-plasms (NENs) in phase II clinical trials
Externí odkaz:
https://doaj.org/article/d8cbde07ab6b41fc9b1e09b37386582c
Publikováno v:
Journal of Personalized Medicine, Vol 5, Iss 3, Pp 243-263 (2015)
Advances in early detection and curative therapies have led to an increased number of cancer survivors over the last twenty years. With this population comes the need to evaluate the late and long term effects of cancer treatment and develop recommen
Externí odkaz:
https://doaj.org/article/4d5546d44f3e445b928c78e0b2d1e8c6
Autor:
Lauren Laderman, Krishnalatha Sreekrishnanilayam, Ramesh K. Pandey, Elizabeth Handorf, Aryeh Blumenreich, Kristen A. Sorice, Shannon M. Lynch, Khadija Cheema, Lavanya Nagappan, Iberia R. Sosa, Efrat Dotan, Namrata Vijayvergia
Publikováno v:
European Journal of Haematology. 110:706-714
Autor:
Jennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, Andrew M. Bellizzi, Emily K Bergsland, Arvind Dasari, Ghassan El-Haddad, Michael Frumovittz, Joshua Meyer, Erik Mittra, Sten Myrehaug, Eric Nakakura, Nitya Raj, Heloisa P Soares, Brian Untch, Namrata Vijayvergia, Jennifer A Chan
Publikováno v:
Endocrine-Related Cancer.
High grade neuroendocrine tumors (G3 NET) and neuroendocrine carcinomas (NEC) are a rare disease entity for which there is a limited amount of prospective data available. It has also been relatively recent that a distinction has been made between G3
Publikováno v:
Hormone and Metabolic Research. 54:795-812
Neuroendocrine tumors (NETs) occur in various regions of the body and present with complex clinical and biochemical phenotypes. The molecular underpinnings that give rise to such varied manifestations have not been completely deciphered. The manageme
Autor:
Ho-Man Yeung, Krishnalatha Sreekrishnanilayam, Caitlin Meeker, Mengying Deng, Sonali Agrawal, Haaris Abdullah, Namrata Vijayvergia
Publikováno v:
Journal of Gastrointestinal Cancer. 54:73-79
This investigation aims to assess the outcomes for second-line therapies to treat extrapulmonary neuroendocrine carcinoma (EP-NEC) after first-line platinum-based chemotherapy.With IRB approval, we conducted a retrospective study of EP-NEC patients t
Autor:
Lisa, Liu, Nicole M, Ross, Elizabeth A, Handorf, Caitlin R, Meeker, Giana, Chen, Donald, Baldwin, Namrata, Vijayvergia
Purpose The coronavirus disease 2019 (COVID-19) pandemic is posing unprecedented challenges for patient care, especially for cancer patients. This study looks at asymptomatic (AS) COVID-19 positivity in cancer patients and its effects on their care.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6270f21382f4ca2bce624b1a21f41492
https://doi.org/10.21203/rs.3.rs-1785577/v1
https://doi.org/10.21203/rs.3.rs-1785577/v1
Autor:
Lisa Liu, Shuning Li, Nishant Gandhi, Alex Patrick Farrell, Emil Lou, Heloisa P. Soares, Bassel Nazha, Jeffrey Swensen, Matthew James Oberley, Chadi Nabhan, Jim Abraham, Wolfgang Michael Korn, Pamela L. Kunz, Namrata Vijayvergia
Publikováno v:
Journal of Clinical Oncology. 41:655-655
655 Background: Demographic variables such as age and sex have long been associated with risk of cancer incidence, therapeutic response, and mortality. In NENs, specifically, studies have shown differences in overall survival based on age at diagnosi
Autor:
Thomas J. George, Greg Yothers, Osama E. Rahma, Theodore S. Hong, Marcia McGory Russell, Y. Nancy You, William Parker, Samuel A. Jacobs, Peter C. Lucas, Linda H. Colangelo, Marc J Gollub, William A. Hall, Lisa A. Kachnic, Madhuri Bajaj, Howard M. Gross, Richard A. Peterson, Jennifer Anne Dorth, Namrata Vijayvergia, Norman Wolmark
Publikováno v:
Journal of Clinical Oncology. 41:7-7
7 Background: This NCTN multi-arm randomized phase II modular clinical trial platform utilizes TNT with parallel experimental arms (EAs) in LARC. EAs are not intended for direct comparison, but rather to concurrently randomized control arm (CA) patie